A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma

2008 ◽  
Vol 63 (5) ◽  
pp. 929-935 ◽  
Author(s):  
Ji Eun Uhm ◽  
Joon Oh Park ◽  
Jeeyun Lee ◽  
Young Suk Park ◽  
Se Hoon Park ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Systemic Chemotherapy ◽  
Phase Ii Study ◽  
First Line

scholarly journals Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

Oncology ◽  
2013 ◽  
Vol 85 (1) ◽  
pp. 44-52 ◽  
Author(s):  
Chih-Hung Hsu ◽  
Yoon Koo Kang ◽  
Tsai-Shen Yang ◽  
Chia-Tung Shun ◽  
Yu-Yun Shao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma ◽  
First Line ◽  
First Line Therapy ◽  
Asian Patients ◽  
Multicenter Phase ◽  
Line Therapy

scholarly journals A Multicenter Phase II Study of Second‐Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First‐Line Sorafenib Monotherapy

2020 ◽  
Vol 25 (9) ◽  
Author(s):  
Zhong‐Zhe Lin ◽  
Bang‐Bin Chen ◽  
Yi‐Ping Hung ◽  
Po‐Hsiang Huang ◽  
Ying‐Chun Shen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line ◽  
First Line ◽  
Multicenter Phase

Phase II study of first-line radioembolization with yttrium-90 glass microspheres for intrahepatic cholangiocarcinoma.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 482-482 ◽  
Author(s):  
Ravi Shridhar ◽  
Jessica M. Frakes ◽  
Binglin Yue ◽  
Richard D. Kim ◽  
Gregory M. Springett ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Phase Ii ◽  
Intrahepatic Cholangiocarcinoma ◽  
Systemic Chemotherapy ◽  
Phase Ii Study ◽  
Performance Status ◽  
Glass Microspheres ◽  
First Line ◽  
Grade 3 ◽  
Yttrium 90

482 Background: The standard of care for unresectable intrahepatic cholangiocarcinoma (ICC) is systemic chemotherapy. The role of liver directed therapy for ICC is controversial given the lack of level I data. We conducted a phase II study to determine the safety and effectiveness of first-line liver directed therapy with radioembolization with yttrium-90 (Y90) glass microspheres for ICC. Methods: Eligible patients were enrolled on an IRB-approved phase II study (NCT01253148). Patients were included if they had no evidence of extrahepatic metastases, Childs-Pugh A, without main portal vein thrombus, bilirubin < 2 mg/dL, ECOG performance status of 0-2, and no prior chemotherapy, liver embolization, or radiation therapy for ICC. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and toxicity. Results: Twenty-five patients were enrolled between 2010 and 2013 with a median followup of 13 months (9-20 months). The median age was 76 years. Twenty patients came off study due to progression or death. The overall response rate was 56%. Median PFS was 6 months (95% CI: 4-12 months). This was likely due to tumors appearing larger after treatment due to tumor inflammation despite a decrease in CA19-9 levels. Univariate (UVA) and multivariate analysis (MVA) failed to identify any prognostic factors associated with PFS. Despite the low median PFS, median OS was 22 months (95% CI: 10 months to upper limit not reached). However, UVA and MVA failed to identify and prognostic factors for OS. Treatment was well tolerated with no reported grade 3 gastrointestinal or general disorder toxicities. Grade 3 ALT, AST, and alkaline phosphatase increase were reported in 4%, 4%, and 8%, respectively. Grade 4 hyperbilirubinemia and thrombocytopenia were reported in 4% and 4%, respectively. There were 2 patient who developed sepsis one patient who died within 30 days of treatment. Conclusions: First-line liver directed therapy with radioembolization with Y90 glass microspheres is a safe and effective treatment for ICC. Further prospective clinical trials are needed to identify the proper sequencing of liver directed therapy and systemic chemotherapy. Clinical trial information: NCT01253148.

scholarly journals Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

2017 ◽  
Vol 22 (7) ◽  
pp. 780 ◽  
Author(s):  
Ghassan K. Abou‐Alfa ◽  
Jean‐Frederic Blanc ◽  
Steven Miles ◽  
Tom Ganten ◽  
Jörg Trojan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma ◽  
First Line

A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4083-4083 ◽  
Author(s):  
A. X. Zhu ◽  
R. S. Finn ◽  
M. F. Mulcahy ◽  
J. S. Gurtler ◽  
W. Sun ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document